GEN Exclusives

More »

GEN News Highlights

More »
Apr 4, 2012

2-to-1 Majority of Respondents to a GEN Poll See Smooth Sailing Ahead for Vivus' Obesity Therapy

  • By a greater than 2-to-1 majority, GEN readers predict FDA will approve without further clinical investigation the weight-loss drug Qnexa, which faces an April 17 deadline for action by the agency. Most respondents (65.3%) predicted FDA will approve Qnexa, while 27.2% anticipate an FDA rejection, and 7.5% were undecided.

    Qnexa’s developer Vivus received welcome news on February 22 when an FDA advisory committee voted 20 to 2 in favor of the drug, concluding that its weight loss benefits outweighed its potential risks. That’s a change from 2010, when the Endocrinologic and Metabolic Drugs Advisory Committee voted 10-6 against FDA approving the drug due to side effects that included serious birth defects and heart problems. Since then, Vivus conducted a one-year clinical trial with new data, while only 12 holdovers from the 2010 panel remain on the current advisory committee. FDA is expected to assuage lingering concerns by asking for a post-approval cardiovascular outcomes study.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?